Results 71 to 80 of about 190,106 (220)

Orally delivered toxin–binding protein protects against diarrhoea in a murine cholera model

Nature Communications
The ongoing seventh cholera pandemic, which began in 1961, poses an escalating threat to public health. There is a need for new cholera control measures, particularly ones that can be produced at low cost, for the one billion people living in cholera ...
Marcus Petersson, Franz G. Zingl, Everardo Rodriguez-Rodriguez, Jakob K. H. Rendsvig, Heidi Heinsøe, Emma Wenzel Arendrup, Natalia Mojica, Dario Segura Peña, Nikolina Sekulić, Ute Krengel, Monica L. Fernández-Quintero, Timothy P. Jenkins, Lone Gram, Matthew K. Waldor, Andreas H. Laustsen, Sandra Wingaard Thrane   +15 more
doaj   +1 more source

Grape extracts inhibit multiple events in the cell biology of cholera intoxication. [PDF]

PLoS ONE, 2013
Vibrio cholerae produces cholera toxin (CT), an AB5 protein toxin that is primarily responsible for the profuse watery diarrhea of cholera. CT is secreted into the extracellular milieu, but the toxin attacks its Gsα target within the cytosol of a host ...
Srikar Reddy, Michael Taylor, Mojun Zhao, Patrick Cherubin, Sandra Geden, Supriyo Ray, David Francis, Ken Teter   +7 more
doaj   +1 more source

In-Depth Characterization of a Re-Engineered Cholera Toxin Manufacturing Process Using Growth-Decoupled Production in Escherichia coli

Toxins, 2022
Non-toxic derivatives of the cholera toxin are extensively used in neuroscience, as neuronal tracers to reveal the location of cells in the central nervous system.
Natalia Danielewicz, Wenyue Dai, Francesca Rosato, Michael E. Webb, Gerald Striedner, Winfried Römer, W. Bruce Turnbull, Juergen Mairhofer   +7 more
doaj   +1 more source

Histidine Supplementation Stabilizes Hearing and Vision and Improves Growth in HARS1‐Related Autosomal Recessive Disorder Associated With Usher‐Like Symptoms

American Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2289-2308, October 2026.
ABSTRACT Autosomal recessive HARS1‐related disorder (originally described as Usher syndrome type 3B) caused by a homozygous Y454S variant in the histidyl‐tRNA synthetase gene (HARS1) is characterized by progressive sensorineural hearing and vision loss and respiratory deterioration with risk for sudden death following febrile illnesses.
Victoria Mok Siu, Rosan Kenana, Rana Chakrabarti, Sarah D. P. Wilhelm, Joseph Andrews, Susan J. Leat, Christina Parker, Michael Miller, Leslie A. Nangle, Wendy McCaul, Ashfia Chowdhury, Natalie Hutchings, Ryan A. Adams, Lauren Guy, Mandy Rhody, Verena Juncal, Marisa I. Mendes, Desiree E. C. Smith, Gajja S. Salomons, Angelica A. Moresco, Daphne L. McCulloch, D. Holmes Morton, Ilka U. Heinemann, C. Anthony Rupar   +23 more
wiley   +1 more source

Vibrio Pathogenicity Island-1: The Master Determinant of Cholera Pathogenesis

Frontiers in Cellular and Infection Microbiology, 2020
Cholera is an acute secretory diarrhoeal disease caused by the bacterium Vibrio cholerae. The key determinants of cholera pathogenicity, cholera toxin (CT), and toxin co-regulated pilus (TCP) are part of the genome of two horizontally acquired Mobile ...
Ashok Kumar, Ashok Kumar, Bhabatosh Das, Bhabatosh Das, Niraj Kumar, Niraj Kumar   +5 more
doaj   +1 more source

Photolabelling of cholera toxin by NAD+ [PDF]

Biochemical Journal, 1987
When cholera toxin is incubated under u.v. light with NAD+ labelled in either the adenine or the nicotinamide moiety, radioactivity becomes covalently bound to the protein. The reaction is specific for cholera toxin, and is inhibited by excess unlabelled NAD+ or NAD analogues. Only the active A 1 chain of the toxin is labelled.
T S, Galloway, R M, Tait, S, van Heyningen   +2 more
openaire   +2 more sources

Characterization of the Immune Response after Oral Cholera Vaccination (OCV) and Effects of Mycophenolate Mofetil on Priming of this Immune Response—A Randomized, Placebo‐Controlled Trial

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1049-1056, October 2026.
Mycophenolate mofetil (MMF) is an immunosuppressive drug widely used by solid organ transplant recipients. Although it is known that MMF suppresses immune responses, its exact effects on specific vaccinations have not been investigated yet. Mucosal vaccinations are increasingly used, such as a cholera vaccination consisting of two oral immunizations ...
Boukje C. Eveleens Maarse, Aliede E. in 't Veld, Hendrika W. Grievink, Manon A.A. Jansen, Matthijs Moerland   +4 more
wiley   +1 more source

INTERACTION OF CHOLERA TOXIN AND TOXIN DERIVATIVES WITH LYMPHOCYTES [PDF]

The Journal of Experimental Medicine, 1974
The interaction of cholera toxin and a number of toxin derivatives, containing different proportions of light and heavy toxin-composing subunits (L and H), with mouse lymphocytes was studied. Experiments with [125I]toxin showed that a single cell can rapidly, within minutes, bind up to 40,000 molecules of toxin, the association constant was estimated ...
J, Holmgren, L, Lindholm, I, Lönnroth
openaire   +2 more sources

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

Cholera toxin gene-positive Vibrio cholerae O1 Ogawa and Inaba strains produce the new cholera toxin

, 1988
Two strains of cholera toxin (CT) gene-positive Vibrio cholerae O1, Ogawa, isolated from patients with diarrhoea and the hypertoxigenic V. cholerae O1, Inaba (569B), were found to produce the new cholera toxin that has earlier been demonstrated to be ...
Saha, Setarunnahar, Sanyal, S. C.
core   +1 more source